NCT02930993

Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors

A Safety and Efficacy Study of Autologous T Cells Engineered to Express Chimeric Antigen Receptor Targeting Mesothelin in Patients With Recurred or Metastatic Malignant Tumors

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: China Meitan General Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, open-label, one center, dose escalation clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to express chimeric antigen receptor targeting mesothelin in adult patients with mesothelin positive, recurrent or metastatic malignant tumors.

Conditions

• Mesothelin Positive Tumors

Interventions

Type	Name	Description
BIOLOGICAL	anti-mesothelin CAR T cells	Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, patients are intravenously infused with anti-mesothelin CAR T cells in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).

Timeline

• Start date: 2016-08-01
• Primary completion: 2018-08-01
• Completion: 2019-08-01
• First posted: 2016-10-12
• Last updated: 2016-10-12

Locations

1 site across 1 country: China